Log in

Neoleukin Therapeutics Stock Price, News & Analysis (NASDAQ:NLTX)

$2.78
+0.04 (+1.46 %)
(As of 10/20/2019 04:00 PM ET)
Today's Range
$2.70
Now: $2.78
$2.83
50-Day Range N/A
52-Week Range
$2.00
Now: $2.78
$4.23
Volume19,647 shs
Average Volume52,177 shs
Market Capitalization$78.23 million
P/E RatioN/A
Dividend YieldN/A
Beta-7.61
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NLTX
CUSIPN/A
CIKN/A
Phone604-629-9223

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25 million
Book Value$3.09 per share

Profitability

Net Income$-31,580,000.00

Miscellaneous

Employees8
Market Cap$78.23 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive NLTX News and Ratings via Email

Sign-up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.


Neoleukin Therapeutics (NASDAQ:NLTX) Frequently Asked Questions

What is Neoleukin Therapeutics' stock symbol?

Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."

When is Neoleukin Therapeutics' next earnings date?

Neoleukin Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Neoleukin Therapeutics.

Has Neoleukin Therapeutics been receiving favorable news coverage?

News articles about NLTX stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neoleukin Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Neoleukin Therapeutics.

Are investors shorting Neoleukin Therapeutics?

Neoleukin Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 69,500 shares, an increase of 167.3% from the August 15th total of 26,000 shares. Based on an average trading volume of 156,900 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.3% of the shares of the stock are short sold. View Neoleukin Therapeutics' Current Options Chain.

Who are some of Neoleukin Therapeutics' key competitors?

What other stocks do shareholders of Neoleukin Therapeutics own?

Who are Neoleukin Therapeutics' key executives?

Neoleukin Therapeutics' management team includes the folowing people:
  • Mr. David J. Main, Co-Founder, Chairman & Pres (Age 54)
  • Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 45)
  • Dr. Jonathan G. Drachman, Chief Exec. Officer (Age 57)
  • Ms. Shelley McCloskey, VP of HR & Admin. (Age 59)

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neoleukin Therapeutics' stock price today?

One share of NLTX stock can currently be purchased for approximately $2.78.

How big of a company is Neoleukin Therapeutics?

Neoleukin Therapeutics has a market capitalization of $78.23 million and generates $25 million in revenue each year. Neoleukin Therapeutics employs 8 workers across the globe.View Additional Information About Neoleukin Therapeutics.

What is Neoleukin Therapeutics' official website?

The official website for Neoleukin Therapeutics is http://www.aqxpharma.com/.

How can I contact Neoleukin Therapeutics?

Neoleukin Therapeutics' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected]


MarketBeat Community Rating for Neoleukin Therapeutics (NASDAQ NLTX)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  6
MarketBeat's community ratings are surveys of what our community members think about Neoleukin Therapeutics and other stocks. Vote "Outperform" if you believe NLTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel